Aspirin sensitivity of PIK3CA-mutated Colorectal Cancer: potential mechanisms revisited
Autor: | Daniella C. N. Hall, Ralf A. Benndorf |
---|---|
Rok vydání: | 2022 |
Předmět: | |
Zdroj: | Cellular and Molecular Life Sciences. 79 |
ISSN: | 1420-9071 1420-682X |
DOI: | 10.1007/s00018-022-04430-y |
Popis: | PIK3CA mutations are amongst the most prevalent somatic mutations in cancer and are associated with resistance to first-line treatment along with low survival rates in a variety of malignancies. There is evidence that patients carrying PIK3CA mutations may benefit from treatment with acetylsalicylic acid, commonly known as aspirin, particularly in the setting of colorectal cancer. In this regard, it has been clarified that Class IA Phosphatidylinositol 3-kinases (PI3K), whose catalytic subunit p110α is encoded by the PIK3CA gene, are involved in signal transduction that regulates cell cycle, cell growth, and metabolism and, if disturbed, induces carcinogenic effects. Although PI3K is associated with pro-inflammatory cyclooxygenase-2 (COX-2) expression and signaling, and COX-2 is among the best-studied targets of aspirin, the mechanisms behind this clinically relevant phenomenon are still unclear. Indeed, there is further evidence that the protective, anti-carcinogenic effect of aspirin in this setting may be mediated in a COX-independent manner. However, until now the understanding of aspirin’s prostaglandin-independent mode of action is poor. This review will provide an overview of the current literature on this topic and aims to analyze possible mechanisms and targets behind the aspirin sensitivity of PIK3CA-mutated cancers. |
Databáze: | OpenAIRE |
Externí odkaz: |